Mentions
Extended reach
Total likes
Video views
AI synopsis
Several discussions criticize the original STAR*D study, highlighting that only 35% remission was found with the new analysis compared to the previously claimed higher rates, using phrases like 'stinks' and 'did not follow its protocols' to express dissatisfaction. Others show moderation with mentions of reanalysis and methodological critiques, indicating a mix of skepticism and engagement that could influence how future depression treatments are interpreted and applied.
Most discussions express skepticism or criticism about the original study’s findings and protocols, indicating disagreement.
Participants show curiosity about the reanalysis and its implications, reflecting moderate interest.
Posts delve into methodological issues and implications of the new analysis, showing some thoughtful engagement.
The conversations challenge prior beliefs about treatment success rates, suggesting a moderate potential impact on clinical perspectives.
Was STAR*D wrong? New analysis finds #depression trial did not follow its protocols. With a more conservative approach, they estimated only 35% remitted after at <=4 treatment attempts, much less than the original 67% https://t.co/FyTcLNWJRH #psychiatry #clinicaltrials https://t.co/dR0aiBKUTv
What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapies in real-world depressed patients? A reanalysis of the STAR*D study's patient-level data with fidelity to the original research https://t.co/obJ7R6ur13
Was STAR*D wrong? New analysis finds #depression trial did not follow its protocols. With a more conservative approach, they estimated 35% remitted after at <=4 treatment attempts, much less than the original 67% -@ChrisAikenMD https://t.co/sV4wrOmx6J #psychiatry #clinicaltrials https://t.co/oISGGxq5hZ
What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapies in real-world depressed patients? A reanalysis of the STAR*D study ... with fidelity to the original research … @BMJ_Open https://t.co/VULGhSJBio
• 1977 Psychiatry: Pretest. Nelson, J. • Original STAR*D (Rush et al. 2006): https://t.co/rUWEFaf5ir… • Re-analysis (Pigott et al. 2023): https://t.co/g6X1VP29mR… https://t.co/rqhHBLg0N8
List of pharma companies mentioned in the disclosure of STAR*D (picture below). • Original STAR*D (Rush et al. 2006): https://t.co/rUWEFaf5ir • Re-analysis (Pigott et al. 2023): https://t.co/g6X1VP29mR • Recent textbook mention of STAR*D Tasman (2024, p1844) • 2006 STAR*D https://t.co/iktyMGHyUl
This episode discusses international alerts regarding ADHD medications, scrutiny of Dr. Fraga's ADHD segments, and the STARD study reanalysis on antidepressant efficacy and patient improvement in real-world settings.
This reanalysis of the STARD study examines how effective antidepressant treatments are and the extent of patient improvement after up to four trials, focusing on real-world clinical settings involving diverse patient…
RT @BadreNicolas: • 1977 Psychiatry: Pretest. Nelson, J. • Original STAR*D (Rush et al. 2006): https://t.co/rUWEFaf5ir… • Re-analysis (Pig…
• 1977 Psychiatry: Pretest. Nelson, J. • Original STAR*D (Rush et al. 2006): https://t.co/rUWEFaf5ir… • Re-analysis (Pigott et al. 2023): https://t.co/g6X1VP29mR… https://t.co/rqhHBLg0N8
RT @BadreNicolas: List of pharma companies mentioned in the disclosure of STAR*D (picture below). • Original STAR*D (Rush et al. 2006): ht…
List of pharma companies mentioned in the disclosure of STAR*D (picture below). • Original STAR*D (Rush et al. 2006): https://t.co/rUWEFaf5ir • Re-analysis (Pigott et al. 2023): https://t.co/g6X1VP29mR • Recent textbook mention of STAR*D Tasman (2024, p1844) • 2006 STAR*D https://t.co/iktyMGHyUl
RT @KeimWalter: What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant ther…
@RobertKennedyJr https://t.co/DoukRGA1dc Give this a read
こちらが最初のSTAR*D再解析論文。こちらでは寛解率はトータルで35%に落ちるよという結果。どう考えたらいいものか。 https://t.co/fxQNGgsDPz
What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapies in real-world depressed patients? e063095.full.pdf https://t.co/haFfWNemn2
What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapies in real-world depressed patients? Reanalysis of the STAR*D study's patient-level data with fidelity to the original research https://t.co/zN2Vie4Qyu
#8 Månadens nyheter: Internationella varningar för ADHD-läkemedel; granskningshärvan kring Fråga doktorn-inslag; STAR*D-skandalen och antidepressiva läkemedel: https://t.co/B6jIKsC3ks #MånadensNyheter #ADHD #FrågaDoktorn #SVT #Granskningsnämnden #STARD #Antidepressiva
RT @Luke_629: What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapie…
RT @psychepi: What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapie…
RT @Luke_629: What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapie…
RT @Luke_629: What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapie…
RT @Luke_629: What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapie…
What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapies in real-world depressed patients? A reanalysis of the STAR*D study's patient-level data to the original research protocol https://t.co/SSeTxSTSV6
RT @Luke_629: What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapie…
RT @Luke_629: What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapie…
RT @Luke_629: What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapie…
RT @Luke_629: What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapie…
RT @Luke_629: What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapie…
What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapies in real-world depressed patients? A reanalysis of the STAR*D study's patient-level data with fidelity to the original research https://t.co/obJ7R6ur13
RT @CarlatPsych: Was STAR*D wrong? New analysis finds #depression trial did not follow its protocols. With a more conservative approach, th…
RT @chrisaikenmd: Was STAR*D wrong? New analysis finds #depression trial did not follow its protocols. With a more conservative approach, t…
Was STAR*D wrong? New analysis finds #depression trial did not follow its protocols. With a more conservative approach, they estimated 35% remitted after at <=4 treatment attempts, much less than the original 67% -@ChrisAikenMD https://t.co/sV4wrOmx6J #psychiatry #clinicaltrials https://t.co/oISGGxq5hZ
RT @chrisaikenmd: Was STAR*D wrong? New analysis finds #depression trial did not follow its protocols. With a more conservative approach, t…
RT @chrisaikenmd: Was STAR*D wrong? New analysis finds #depression trial did not follow its protocols. With a more conservative approach, t…
RT @chrisaikenmd: Was STAR*D wrong? New analysis finds #depression trial did not follow its protocols. With a more conservative approach, t…
RT @chrisaikenmd: Was STAR*D wrong? New analysis finds #depression trial did not follow its protocols. With a more conservative approach, t…
RT @chrisaikenmd: Was STAR*D wrong? New analysis finds #depression trial did not follow its protocols. With a more conservative approach, t…
RT @chrisaikenmd: Was STAR*D wrong? New analysis finds #depression trial did not follow its protocols. With a more conservative approach, t…
Was STAR*D wrong? New analysis finds #depression trial did not follow its protocols. With a more conservative approach, they estimated only 35% remitted after at <=4 treatment attempts, much less than the original 67% https://t.co/FyTcLNWJRH #psychiatry #clinicaltrials https://t.co/dR0aiBKUTv
RT @Altostrata: Gold standard STAR*D study supposedly showing remission from antidepressant treatment continues to stink. 35% remitted. Wh…
RT @Altostrata: Gold standard STAR*D study supposedly showing remission from antidepressant treatment continues to stink. 35% remitted. Wh…
Gold standard STAR*D study supposedly showing remission from antidepressant treatment continues to stink. 35% remitted. What are the treatment remission, response and extent of improvement rates...A reanalysis of the STAR*D study’s patient-level data.... https://t.co/dxKxBKc1ST
RT @MedicatingNorm1: Article from the BMJ: "What are the treatment remission, response and extent of improvement rates after up to four tri…
Article from the BMJ: "What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapies in real-world depressed patients?" Article Link: https://t.co/ABoWFCzxN3 #antidepressants
RT @psychepi: What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapie…
RT @psychepi: What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapie…
RT @psychepi: What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapie…
RT @psychepi: What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapie…
RT @psychepi: What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapie…
RT @psychepi: What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapie…
RT @psychepi: What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapie…
RT @psychepi: What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapie…
RT @psychepi: What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapie…
RT @psychepi: What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapie…
RT @psychepi: What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapie…
RT @psychepi: What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapie…
RT @psychepi: What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapie…
RT @psychepi: What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapie…
RT @psychepi: What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapie…
RT @psychepi: What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapie…
RT @psychepi: What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapie…
What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapies in real-world depressed patients? A reanalysis of the STAR*D study ... with fidelity to the original research … @BMJ_Open https://t.co/VULGhSJBio
Open access Original research. BMJ Open: first published as 10.1136/bmjopen-2022-063095 on 25 July 2023. Downloaded from http://bmjopen.bmj.com/ on ...
BMJ Open, 13(7), e063095. https://doi.org/10.1136/bmjopen-2022-063095. • Schwarzbold, M., Diaz, A., Martins, E. T., Rufino, A., Amante, L. N., Thais, M. E. ...
https://doi.org/10.1136/bmjopen-2022-063095. एल्गो के स्टेप्स अभी भी ठीक हैं, लेकिन आज तो और भी ...
... BMJ open, 13(7), e063095. https://doi.org/10.1136/bmjopen-2022-063095. ขั้นตอนในอัลกอริทึมยังโอเคอยู่ แต่แน่นอนว่าวันนี้มีตัวเลือกเยอะกว่าเดิม.
BMJ open, 13(7), e063095. https://doi.org/10.1136/bmjopen-2022-063095. Steps in the algo are still alright, but of course today there are ...
BMJ open, 13(7), e063095. https://doi.org/10.1136/bmjopen-2022-063095. I passaggi nell'algoritmo sono ancora a posto, ma ovviamente oggi ci ...
doi: 10.1136/bmjopen-2022-063095. 4. FDA Clears NeuroStar TMS for Treatment of MDD in Adolescents. Disclaimer: Dr. Brenner in is private ...
... patient-level data with fidelity to the original research protocol HE Pigott et al doi:10.1136/bmjopen-2022-063095.
BMJ Open, 0, e063095. doi:10.1136/bmjopen-2022-063095 (Link). Previous articlePsychosis sensitivity; we lose contact with our body. Next ...
CM
Lバ
CP
MR
NB
AX
FM
KD
F
た
ED
WK
お映
DM
青
TK
KP
FD
T
T精
L
あ
YN
MA
AF
G
MP
AA
AL
DA
MP
SS
J
WC
MN
BD
LS
CW
ZC
MP
MD
DP
SS
BH
RP
DD
PG
IV
AP
RS
RR
RG